Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

II, Raad; JR, Graybill; AB, Bustamante; OA, Cornely; V, Gaona-Flores; C, Afif; DR, Graham; RN, Greenberg; S, Hadley; A, Langston; R, Negroni; JR, Perfect; P, Pitisuttithum; A, Restrepo; G, Schiller; L, Pedicone; AJ, Ullmann

doi:10.1086/504328

Public

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

Shared by NobleBlocks on May 8, 2006 • 12:00 AM UTC

Authors:

Raad II

Graybill JR

Bustamante AB

Abstract

Background Invasive fungal infections are found most frequently in immunosuppressed and critically ill hospitalized patients. Antifungal therapy is often required for long periods. Safety data from the clinical development program of the triazole antifungal agent, posaconazole, were analyzed.Methods...

Discussions